Journal Article

Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction

Ponikowski Piotr, Filippatos Gerasimos, Martens Pieter, Ng, Leong L, Anker, Stefan D, Samani, Nilesh J, Damman, Kevin, Cleland, John G, Hillege, Hans L, ter Maaten Jozine M, Voors, Adriaan A, Lang, Chim C, Mullens Wilfried, Dickstein, Kenneth, Zannad Faiez, Metra Marco, van Veldhuisen Dirk J

2020

Overview

BackgroundLoop diuretics are frequently prescribed to patients with heart failure and reduced ejection fraction (HFrEF) for the treatment of congestion; however, they might hamper uptitration of inhibitors of the renin–angiotensin system.MethodsLoop diuretic dose at baseline was recorded in 2338 patients with HFrEF enrolled in BIOSTAT-CHF, an international study of HF patients on loop diuretic therapy who were eligible for uptitration of angiotensin-converting enzyme inhibitors (ACEi)/mineralocorticoid receptor antagonists (MRA). The association between loop diuretic dose and uptitration of ACEi/MRA to percentage of target dose was adjusted for a previously published model for likelihood of uptitration and a propensity score.ResultsBaseline median loop diuretic dose was 40 [40–100] mg of furosemide or equivalent. Higher doses of loop diuretics were associated with higher NYHA class and higher levels of NT-proBNP, more severe signs and symptoms of congestion, more frequent MRA use, and lower doses of ACEi reached at 3 and 9 months (all P < 0.01). After propensity adjustment, higher doses of loop diuretics remained significantly associated with poorer uptitration of ACEi (Beta per log doubling of loop diuretic dose: − 1.66, P = 0.021), but not with uptitration of MRAs (P = 0.758). Higher doses of loop diuretics were independently associated with an increased risk of all-cause mortality or HF hospitalization [HR per doubling of loop diuretic dose: 1.06 (1.01–1.12), P = 0.021].ConclusionsHigher doses of loop diuretics limited uptitration of ACEi in patients with HFrEF and were associated with a higher risk of death and/or HF hospitalization, independent of their lower likelihood of uptitration and higher baseline risk.Graphic abstract This figure was created with images adapted from Servier Medical Art licensed under a Creative Commons Attribution 3.0

• Publisher: Springer Nature B.V
• Subject: Angiotensin / Angiotensin-converting enzyme inhibitors / Congestion / Congestive heart failure / Diuretics / Dosage / Ejection fraction / Enzymes / Furosemide / Heart failure / Patients / Peptidyl-dipeptidase A / Renin / Risk / Signs and symptoms